KromaTiD Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
35
- Latest Deal Type
-
2ndary - Private
- Investors
-
7
KromaTiD General Information
Description
Developer of next-gen cytogenetic products focused on discovering, detecting, and diagnosing genomic rearrangements in the areas of oncology and rare diseases. The company's molecular cytogenetic and GeneTracker tests discover, detect, and diagnose the widest range of disease-causing mutations, including inversions and translocations, in a single test, enabling research teams in academia, pharma, and biopharma to accelerate the delivery of novel therapeutics to the patients who need them.
Contact Information
Website
www.kromatid.comCorporate Office
- 6899 Winchester Cir
- Street 100
- Boulder, CO 80301
- United States
Corporate Office
- 6899 Winchester Cir
- Street 100
- Boulder, CO 80301
- United States
KromaTiD Timeline
KromaTiD Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Secondary Transaction - Private | 15-Feb-2026 | Completed | Generating Revenue | |||
| 14. Later Stage VC (Series C) | 10-Jul-2025 | Completed | Generating Revenue | |||
| 13. Later Stage VC (Series B) | 15-Oct-2021 | Completed | Generating Revenue | |||
| 12. Grant | 15-Jan-2021 | Completed | Generating Revenue | |||
| 11. Grant | 04-Aug-2020 | Completed | Generating Revenue | |||
| 10. Debt - PPP | 15-Apr-2020 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series A1) | 12-Sep-2019 | Completed | Generating Revenue | |||
| 8. Grant | 10-Jun-2019 | Completed | Generating Revenue | |||
| 7. Debt - General | 01-Dec-2018 | $800K | $5.8M | Completed | Generating Revenue | |
| 6. Later Stage VC (Series A) | 31-May-2017 | $5M | $5M | Completed | Generating Revenue |
KromaTiD Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A1 | 3,850,000 | $0.5 | $0.5 | 1x | $0.5 | 5.92% | ||
| Series A | 12,247,955 | $0.27 | $0.27 | 1x | $0.27 | 18.84% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
KromaTiD Comparisons
Industry
Financing
Details
KromaTiD Competitors (48)
One of KromaTiD’s 48 competitors is Biocare Medical (Discovery Tools), a Formerly PE-Backed company based in Pacheco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biocare Medical (Discovery Tools) | Formerly PE-Backed | Pacheco, CA | ||||
| Mission Bio | Venture Capital-Backed | San Francisco, CA | ||||
| Arbor Biotechnologies | Venture Capital-Backed | Cambridge, MA | ||||
| Deep Genomics | Venture Capital-Backed | Toronto, Canada | ||||
| GemPharmatech | Formerly VC-backed | Nanjing, China |
KromaTiD Patents
KromaTiD Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4347876-A1 | Methods, compositions, and kits for determining chromosome stability, genotoxicity, and insert number | Active | 22-Apr-2022 | ||
| EP-4347876-B1 | Methods, compositions, and kits for determining chromosome stability, genotoxicity, and insert number | Active | 22-Apr-2022 | ||
| EP-4570920-A2 | Methods, compositions, and kits for determining chromosome stability, genotoxicity, and insert number | Pending | 22-Apr-2022 | ||
| EP-4570920-A3 | Methods, compositions, and kits for determining chromosome stability, genotoxicity, and insert number | Pending | 22-Apr-2022 | ||
| US-20260132446-A1 | Methods, compositions, and kits for determining chromosome stability, genotoxicity, and insert number | Pending | 22-Apr-2022 | C12Q1/6827 |
KromaTiD Signals
KromaTiD Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BroadOak Capital Partners | Growth/Expansion | Majority | ||
| National Institutes of Health | Government | |||
| First Capital Ventures | Venture Capital | Minority | ||
| U.S. Department of Health and Human Services | Government | |||
| Innosphere Ventures | Accelerator/Incubator | Minority |
KromaTiD FAQs
-
When was KromaTiD founded?
KromaTiD was founded in 2007.
-
Where is KromaTiD headquartered?
KromaTiD is headquartered in Boulder, CO.
-
What is the size of KromaTiD?
KromaTiD has 35 total employees.
-
What industry is KromaTiD in?
KromaTiD’s primary industry is Biotechnology.
-
Is KromaTiD a private or public company?
KromaTiD is a Private company.
-
What is KromaTiD’s current revenue?
The current revenue for KromaTiD is .
-
How much funding has KromaTiD raised over time?
KromaTiD has raised $23.6M.
-
Who are KromaTiD’s investors?
BroadOak Capital Partners, National Institutes of Health, First Capital Ventures, U.S. Department of Health and Human Services, and Innosphere Ventures are 5 of 7 investors who have invested in KromaTiD.
-
Who are KromaTiD’s competitors?
Biocare Medical (Discovery Tools), Mission Bio, Arbor Biotechnologies, Deep Genomics, and GemPharmatech are some of the 48 competitors of KromaTiD.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process